Myriad Genetics SEC Filings

Myriad Genetics (MYGN)October 24, 2025, its Chief Accounting Officer, Natalie Munk, no longer serves in that role and is no longer subject to Section 16 reporting. Following the reported change, the filing lists 45,167 shares of common stock beneficially owned, held directly.

Myriad Genetics, Inc. finalized a Separation Agreement with former CFO Scott J. Leffler after his employment ended at the close of business on September 2, 2025. The agreement becomes effective on October 9, 2025 if not revoked and provides a lump-sum severance payment of $1,239,384 under the executive's existing Severance and Change of Control Agreement. The Company also agreed to accelerate vesting of time-based equity awards scheduled to vest within two years of the Separation Date, with annual installments treated as monthly vesting over that period. Outstanding performance-based awards remain subject to their original performance conditions and may vest if those conditions are met within two years. The separation includes customary non-compete, non-solicitation, and non-disparagement covenants and a release of claims.

Myriad Genetics reported that Natalie Munk, its Senior Vice President and Chief Accounting Officer, notified the company on September 29, 2025 that she will resign effective October 24, 2025. The filing states her departure is not the result of any disagreement with the company on operations, policies or practices. To maintain accounting leadership, the Board designated Benjamin R. Wheeler, the company’s Chief Financial Officer since August 2025, to serve additionally as principal accounting officer upon Ms. Munk’s departure. The filing notes Mr. Wheeler has worked at Myriad for over a decade, is a CPA, holds accounting degrees from Brigham Young University, and received no additional compensation for the designation.

Myriad Genetics insider transaction summary: Chief Operating Officer Mark Verratti reported a compensatory disposition on 09/21/2025 where 1,085 shares of Myriad common stock were disposed of at an average price of $7.77 per share. The filing explains these shares were withheld by the company to satisfy tax-withholding obligations related to the vesting of restricted stock units. After the withholding, Verratti beneficially owns 381,826 shares directly. The Form 4 was signed on 09/22/2025 and indicates a routine tax-related transaction following equity vesting.

Natalie Munk, Chief Accounting Officer of Myriad Genetics (MYGN), reported a disposition of common stock related to tax withholding on vested restricted stock units. The Form 4 shows a sale/disposition code (F) for 962 shares at a reported price of $7.77, leaving the reporting person with 45,167 shares held directly. The filing states the withheld shares were used to satisfy tax withholding obligations tied to the vesting of restricted stock units and that the number withheld was determined using Myriad's closing stock price on September 19, 2025. The Form 4 was signed on behalf of the reporting person.

Benjamin R. Wheeler, Chief Financial Officer of Myriad Genetics (MYGN), reported a Form 4 showing shares withheld to cover taxes on vested restricted stock units. On 09/21/2025 the filing records 2,559 shares disposed (withheld) at an indicated price of $7.77 per share. After this withholding, Mr. Wheeler beneficially owns 92,651 shares. The filing explains the shares were withheld to satisfy tax withholding obligations and that the withheld amount was determined using Myriad's closing price on September 19, 2025.

Margaret Ancona, EVP, Strategy & Transformation at Myriad Genetics (MYGN), reported a non-derivative transaction on 09/21/2025 in which 958 shares of Myriad common stock were withheld at an effective price of $7.77 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the withholding, the reporting person beneficially owns 127,726 shares directly. The Form 4 filing indicates the withholding was calculated using the closing price on September 19, 2025, and the Form was submitted on 09/22/2025.

Jennifer Lynne Fox, identified as Chief Legal Officer and a director of Myriad Genetics, reported a transaction dated 09/03/2025 on Form 4. The filing shows 4,435 shares of Myriad common stock were withheld at a price of $6.80 per share to satisfy tax withholding obligations related to the vesting of restricted stock units. After the withholding, the reporting person beneficially owned 120,481 shares directly. The form was signed on behalf of the reporting person by Justin Hunter on 09/04/2025.

Myriad Genetics insider grant and resulting ownership: Benjamin R. Wheeler, identified as the company's Chief Financial Officer, received a grant of 60,000 time-based restricted stock units (RSUs) on 08/16/2025. The RSUs were granted at a reported price of $0 and represent contingent rights to one share of common stock each. Following the grant, the reporting person beneficially owned 95,210 shares. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. The Form 4 filing is dated 08/19/2025 and bears the signature entry by Justin Hunter on behalf of Benjamin R. Wheeler.